Yang Sheng-Lan, Luo Ying-Ying, Chen Min, Zhou Yan-Ping, Lu Fu-Rong, Deng Dan-Fang, Wu Yan-Ran
Department of Traditional Chinese Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, PR China.
Department of Geriatric, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, PR China.
HPB (Oxford). 2017 Oct;19(10):835-842. doi: 10.1016/j.hpb.2017.06.002. Epub 2017 Jul 19.
The aim of this meta-analysis was to evaluate the prognosis of patients with different types of hepatocellular cancer (HCC) recurrence following hepatectomy. Specifically, it evaluated overall survival and disease-free survival in HCC patients with multicentric occurrence (MO) or intrahepatic metastasis (IM).
Medline, Cochrane, EMBASE, and Google Scholar were searched until August 22, 2016 using the following search terms: hepatocellular carcinoma, multicentric occurrence, intrahepatic metastasis, early recurrence, and late recurrence. Prospective, retrospective, and case control studies were included.
The pooled results showed that patients in the MO group had lower risk of death than the IM group (pooled HR = 0.495, 95% CI = 0.378 to 0.648, P < 0.001). The MO group also had significantly longer disease-free survival than the IM group (pooled HR = 0.774, 95% CI = 0.663 to 0.903, P = 0.001). Sensitivity analysis indicated that no one study dominated the findings and that the data are robust. Overall the included studies were of good quality.
This study found that MO patients have greater survival following surgery than IM patients, indicating the prognosis of MO patients is significantly better than that for IM patients.
本荟萃分析旨在评估肝切除术后不同类型肝细胞癌(HCC)复发患者的预后。具体而言,评估多中心发生(MO)或肝内转移(IM)的HCC患者的总生存期和无病生存期。
使用以下检索词在Medline、Cochrane、EMBASE和谷歌学术上进行检索,直至2016年8月22日:肝细胞癌、多中心发生、肝内转移、早期复发和晚期复发。纳入前瞻性、回顾性和病例对照研究。
汇总结果显示,MO组患者的死亡风险低于IM组(汇总风险比[HR]=0.495,95%置信区间[CI]=0.378至0.648,P<0.001)。MO组的无病生存期也显著长于IM组(汇总HR=0.774,95%CI=0.663至0.903,P=0.001)。敏感性分析表明,没有一项研究主导研究结果,数据可靠。总体而言,纳入的研究质量良好。
本研究发现,MO患者术后生存率高于IM患者,表明MO患者的预后明显优于IM患者。